ReviewDie Ophthalmologie2025
[Progression assessment of glaucoma].
Review in Die Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Future visual field prediction in glaucoma: an application of first-order autoregressive approach.International ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progression monitoring is essential for glaucoma management. In addition to perimetry, optical coherence tomography (OCT) has become established as a valuable supplement. It provides morphological information on the retinal nerve fiber layer (RNFL), the neuroretinal rim and the density of retinal ganglion cells in the macula. Event-based and trend-based analyses can be used for the quantitative analysis of glaucoma progression. Various biomarkers have stage-dependent strengths and weaknesses and should be complementarily applied. The minimization of measurement errors is important for valid progression analyses. In the future other techniques and artificial intelligence (AI) could improve the progression analysis.
Indexed as
Identifiers
40906058What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.